share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  06/18 12:54
Moomoo AI 已提取核心訊息
On June 17, 2024, Mangoceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, with a quorum achieved through the presence of 20,115,314 shares, against a total of 24,819,500 shares outstanding as of the record date, May 6, 2024. During the meeting, shareholders voted on six key proposals. The election of directors Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers was confirmed. Additionally, the issuance of over 19.99% of outstanding common stock upon conversion of Series B Convertible Preferred Stock and certain warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). Similar approval was granted for the issuance of stock pursuant to an Equity Purchase Agreement and for the full issuance of shares related to the 6% Series C Convertible Cumulative Preferred Stock. Turner, Stone & Company, L.L.P. was appointed as the independent auditors for the fiscal year ending December 31, 2024. A proposal to adjourn the meeting for additional proxy solicitation was also approved, but the adjournment was not necessary.
On June 17, 2024, Mangoceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, with a quorum achieved through the presence of 20,115,314 shares, against a total of 24,819,500 shares outstanding as of the record date, May 6, 2024. During the meeting, shareholders voted on six key proposals. The election of directors Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers was confirmed. Additionally, the issuance of over 19.99% of outstanding common stock upon conversion of Series B Convertible Preferred Stock and certain warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). Similar approval was granted for the issuance of stock pursuant to an Equity Purchase Agreement and for the full issuance of shares related to the 6% Series C Convertible Cumulative Preferred Stock. Turner, Stone & Company, L.L.P. was appointed as the independent auditors for the fiscal year ending December 31, 2024. A proposal to adjourn the meeting for additional proxy solicitation was also approved, but the adjournment was not necessary.
2024年6月17日，Mangoceuticals，Inc.進行了其2024股東年會，通過出席20115314股份的議案達成法定人數，而根據記錄日期2024年5月6日，總共有24819500股份。會議期間，股東對六個關鍵提案進行了投票。選舉董事Jacob D. Cohen，Lorraine D'Alessio，Alex P. Hamilton和Dr. Kenny Myers被確認。此外，董事會批准了基於Series B可轉換優先股和某些認股權轉換而發行的超過19.99％的流通普通股，其合規性符合Nasdaq的上市規則5635（d）。類似的，也獲得了根據股權購買協議發行股票以及全額髮行與6％Series C可轉換累積優先股有關的股份的批准。Turner，Stone＆Company，L.L.P.被任命爲截至2024年12月31日的財政年度的獨立核數師。關於將會議休會進行額外的代理徵求的提案也獲得了批准，但休會並不必要。
2024年6月17日，Mangoceuticals，Inc.進行了其2024股東年會，通過出席20115314股份的議案達成法定人數，而根據記錄日期2024年5月6日，總共有24819500股份。會議期間，股東對六個關鍵提案進行了投票。選舉董事Jacob D. Cohen，Lorraine D'Alessio，Alex P. Hamilton和Dr. Kenny Myers被確認。此外，董事會批准了基於Series B可轉換優先股和某些認股權轉換而發行的超過19.99％的流通普通股，其合規性符合Nasdaq的上市規則5635（d）。類似的，也獲得了根據股權購買協議發行股票以及全額髮行與6％Series C可轉換累積優先股有關的股份的批准。Turner，Stone＆Company，L.L.P.被任命爲截至2024年12月31日的財政年度的獨立核數師。關於將會議休會進行額外的代理徵求的提案也獲得了批准，但休會並不必要。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息